On May 11, 2021 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, reported that it had filed a patent application under the Patent Cooperation Treaty (PCT) for novel formulations developed for treatment of various cancer types (Press release, Cannabics Pharmaceuticals, MAY 11, 2021, View Source [SID1234579722]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Said patent application includes ample preclinical supporting data collected from in-vitro experiments performed in the company’s in-house drug discovery facilities in Israel, as well as from in-vivo experiments performed on mice.

Gabriel Yariv, Cannabics Pharmaceuticals President and COO: "After a rigorous process of screening, testing and analyzing a variety of unique molecular compounds, and their effect on human biopsies and cancer cell lines, we have identified specific formulations that stand out in terms of their performance. These formulations are detailed in the current PCT application, and we plan to turn them into new drug candidates for specific cancer treatments in the near future".

This news follows the company’s announcement from last week concerning "Notice of Allowance" received by the company from The Mexican Patent and Trademark Office (IMPI) on a separate patent application.